Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Rosario García‐Campelo, Óscar Arrieta, Bartomeu Massutí, Delvys Rodríguez‐Abreu, Ana Laura Ortega Granados, Margarita Majem, David Vicente, P. Lianes, Joaquim Bosch‐Barrera, Amelia Insa, Manuel Dómine, Noemı́ Reguart, M. Guirado, María Ángeles Sala, Sergio Vázquez‐Estévez, Reyes Bernabé Caro, Ana Drozdowskyj, Ana Verdú, Niki Karachaliou, Miguel Ángel Molina‐Vila, Rafael Rosell
Topics & Concepts
GefitinibMedicineOlaparibOncologyLung cancerInternal medicinenon-small cell lung cancer (NSCLC)Randomized controlled trialCancerEpidermal growth factor receptorPoly ADP ribose polymerasePolymeraseBiochemistryA549 cellGeneChemistryLung Cancer Treatments and MutationsLung Cancer Research StudiesPARP inhibition in cancer therapy